Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT04509765 · ClinicalTrials.gov registry record · NA

A Phase II Single-arm Study of Total Body Irradiation With Linac Based VMAT and IGRT

A NA study, sponsored by NYU Langone Health.

Completed
Registry status
NA
Development phase
36
Enrollment target

NCT04509765: Completed NA study, sponsored by NYU Langone Health.

NCT04509765 is a NA study that has completed, run by NYU Langone Health. The registered enrollment target is 36 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (97% lower). According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT04509765, a NA study, has completed, sponsored by NYU Langone Health.

COMPLETED
Registry status
NA
Development phase
36 participants
Enrollment target

Study Summary

Single institution study of safety of linac based VMAT TBI for myeloablative treatment in hematologic malignancies.

Primary Outcome

Excellent coverage while sparing the lung is quantified by meeting the following dosimetric parameters (all parameters must be met): 1. V100%= \>90% (90% of PTV volume getting 100% of the dose). 2. D98\>85% (98% of the volume getting at least 85% of the dose). 3. Mean Lung dose \<900cGy.

Interventions

  • RADIATION Linac Based VMAT TBI

Trial Details

FieldValue
Enrollment Target 36 participants
Start Date 2020-09-22
Est. Completion 2025-02-11
Phase NA
NYU Langone Health

1,164 total trials

What the finished NCT04509765 record still lists

NCT04509765 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 36 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (97% lower).

The record links to 0 conditions, and to 1 intervention - of which Linac Based VMAT TBI is the first listed.

NCT04509765 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT04509765 about?

NCT04509765 is a clinical study titled "A Phase II Single-arm Study of Total Body Irradiation With Linac Based VMAT and IGRT". Single institution study of safety of linac based VMAT TBI for myeloablative treatment in hematologic malignancies.

What is the current status of trial NCT04509765?

This trial is currently completed. It is a NA study. The enrollment target is 36 participants. The study started on 2020-09-22. Estimated completion is 2025-02-11.

What interventions are being tested in trial NCT04509765?

The interventions under investigation include: Linac Based VMAT TBI (RADIATION).

Who is sponsoring clinical trial NCT04509765?

This trial is sponsored by NYU Langone Health, which has 1,164 total clinical trials registered on ClinicalTrials.gov.

How this trial's enrollment target compares

Where NCT04509765's enrollment target sits among peer trials

36 1541st of 2000 higher than 437 of 2,000 other NA trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT00929006 · 36 participants · Early Phase 1

    Acute Progesterone Suppression of Wake vs. Sleep Luteinizing Hormone Pulse Frequency in Pubertal Girls With and Without Hyperandrogenism

  • NCT01891318 · 36 participants · Phase 1

    Neoadjuvant Radiosurgery for Resectable Brain Metastases: Phase I/II Study

  • NCT02291848 · 36 participants · Phase 1

    Tumor-Associated Antigen-Specific Cytotoxic T-Lymphocytes for Multiple Myeloma

  • NCT02366819 · 36 participants · Phase 4

    Genetic Analysis-Guided Irinotecan Hydrochloride Dosing of mFOLFIRINOX in Treating Patients With Locally Advanced Gastroesophageal or Stomach Cancer

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT04509765, the US trial registry maintained by the National Library of Medicine. NCT04509765 (small enrollment · none site footprint · completed) retrieved and formatted by PlainTrial, see methodology.